Prodrugs of prostate specific membrane antigen (PSMA) inhibitor
US-9988407-B2 · Jun 5, 2018 · US
Prodrugs of prostate specific membrane antigen (PSMA) inhibitor
US10544176B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10544176-B2 |
| Application number | US-201815968074-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 1, 2018 |
| Priority date | Aug 6, 2014 |
| Publication date | Jan 28, 2020 |
| Grant date | Jan 28, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Methods and compounds are disclosed for treating a disease or condition by inhibiting PSMA (Prostate Specific Membrane Antigen) using prodrugs of 2-PMPA.
First claim
Opening claim text (preview).
That which is claimed: 1. A method for treating a disease or a condition, the method comprising administering to a subject in need of treatment thereof, a compound having the following structure: or a pharmaceutical composition thereof, in an amount effective for treating the disease or condition, wherein the disease or condition is selected from the group consisting of multiple sclerosis (MS), colon cancer, prostate cancer, angiogenesis, and inflammatory bowel disease. 2. A method for treating a neurological disease, the method comprising administering to a subject in need of treatment thereof, a compound having the following structure: or a pharmaceutical composition thereof, in an amount effective for treating the disease or condition, wherein the neurodegenerative disease is selected from the group consisting of amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), Alzheimer's disease (AD), Huntington's disease, dementia with Lewy Bodies (DLB), schizophrenia, pain, epilepsy, stroke, and traumatic brain injury (TBI). 3. A compound selected from the group consisting of: 4. A pharmaceutical composition comprising a compound of claim 3 and a pharmaceutically acceptable excipient.
Assignees
Inventors
Classifications
for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title
Drugs for disorders of the nervous system · CPC title
Esters of acyclic acids which can have further substituents on alkyl · CPC title
Esters with hydroxyaryl compounds · CPC title
Esters with arylalkanols · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10544176B2 cover?
- Methods and compounds are disclosed for treating a disease or condition by inhibiting PSMA (Prostate Specific Membrane Antigen) using prodrugs of 2-PMPA.
- Who is the assignee on this patent?
- Univ Johns Hopkins, Inst Of Organic Chemistry And Biochemistry As Cr V V I
- What technology area does this patent fall under?
- Primary CPC classification C07F9/65586. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).